阿波利波蛋白A-I输液对心血管事件的影响 - 通过中性粒细胞 - 淋巴细胞比率和LDL胆固醇水平的MI后心血管事件
Sem A O F Rikken1, C Michael Gibson2, M Cecilia Bahit3
1Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands; Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands; Baim Institute for Clinical Research, Boston, Massachusetts, USA.
JACC. Advances
|April 27, 2025
概括
升高的中性粒细胞-淋巴细胞比率 (NLR) 预测急性心肌梗塞 (AMI) 后的主要不良心血管事件 (MACE). 在患有高NLR和LDL-C的患者中,CSL112疗法降低了MACE.
科学领域:
- 心脏病学 心脏病学
- 炎症研究 炎症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 在AEGIS-II试验中,研究了CSL112 (阿波蛋白A-I疗法) 针对急性心肌梗塞 (AMI) 后心血管事件的减少.
- 探索性分析检查了基线中性粒细胞-淋巴细胞比率 (NLR) 和LDL-C对CSL112疗效的影响,考虑到CSL112的抗炎潜力.
研究的目的:
- 为了评估基线NLR和心血管事件在后AMI患者之间的关联.
- 为了确定NLR和LDL-C是否会改变CSL112治疗的疗效.
主要方法:
- 18,219名AMI患者每周接受4次CSL112或安慰剂输液.
- 主要终点:心血管死亡,心肌梗塞或中风 (MACE) 的复合.
- 考克斯模型通过二分化的NLR分析风险;评估了与NLR和LDL-C的治疗相互作用.
主要成果:
- 升高的基线NLR (>中位数) 与90天后MACE的显著更高风险相关 (HR:1.40),持续长期.
- 在患有高NLR和LDL-C≥100 mg/dL (HR:0.63) 的患者中,CSL112在90天后降低了MACE,具有持续的益处.
- 在CSL112治疗和NLR,治疗,NLR和LDL-C之间发现了显著的相互作用.
结论:
- 基线升高的NLR是后AMI患者中MACE的预测指标.
- CSL112在患有高NLR和高LDL-C (≥100 mg/dL) 的患者中显示了MACE的降低.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...